Metabolic and bariatric surgery yields significant body weight variations in sarcopenic obesity versus non-sarcopenic obesityMetabolic surgery helps people with sarcopenic obesity lose weight and improve health

This systematic review and meta-analysis examined the efficacy of metabolic and bariatric surgery (MBS) within a global population of 1704 patients with sarcopenic obesity. The study setting encompassed locations all over the world, reflecting a broad international scope. The primary comparison involved sarcopenic obesity groups against non-sarcopenic obesity groups. The analysis focused on variations of body weight and body mass index from initial to follow-up, alongside the proportion of total weight loss, the proportion of excess weight loss, and the remission of comorbidities. Secondary outcomes included the incidence of postoperative complications. The review aimed to provide reference value for the implementation of reasonable intervention in this specific population.

Regarding body weight, the analysis found more significant variations in the sarcopenic obesity group compared to the non-sarcopenic obesity group. The effect size was reported as a standardized mean difference of .89. The 95% confidence interval ranged from .32 to 1.46, with a P value of .002. For body mass index, the sarcopenic obesity group also demonstrated more significant variations. The effect size was a standardized mean difference of 1.08. The 95% confidence interval for this outcome ranged from .41 to 1.76, and the P value was .0016.

In terms of weight loss metrics, the percentage of total weight loss showed a trend toward higher values in the sarcopenic obesity group. The effect size was a standardized mean difference of .30. The 95% confidence interval was .06 to .66, with a P value of .09. Similarly, the percentage of excess weight loss exhibited a trend toward higher values in the sarcopenic obesity group. The effect size was a standardized mean difference of .57. The 95% confidence interval ranged from .28 to 1.42, and the P value was .08.

The remission of comorbidities showed no significant difference between the two groups. The P values for all comparisons in this category were greater than .05. Regarding safety, the incidence of postoperative complications was similar between the sarcopenic obesity and non-sarcopenic obesity groups. The relative risk was 1.78. The 95% confidence interval for this relative risk ranged from .93 to 3.41, with a P value greater than .05. Serious adverse events were not reported in the source data.

Methodological limitations were not explicitly detailed in the provided data, though the observational nature of the underlying studies introduces potential biases. The follow-up duration was not reported. Funding or conflicts of interest were not reported. The review notes that these results provide some reference value for the implementation of reasonable intervention in this population. However, the lack of reported absolute numbers and specific dosing protocols limits direct clinical application. The trends observed in weight loss percentages did not reach statistical significance, suggesting that while the direction of effect favors the sarcopenic obesity group, the magnitude may be modest.

Clinical implications suggest that metabolic and bariatric surgery may be a viable option for sarcopenic obesity, potentially offering comparable safety profiles to non-sarcopenic obesity groups. However, the uncertainty regarding long-term outcomes and the lack of detailed safety data necessitate caution. Further research is needed to clarify the optimal patient selection criteria and to confirm the durability of weight loss benefits in this specific population. The absence of reported discontinuations and tolerability data further limits the ability to fully assess the risk-benefit profile for individual patients.